1. Volume 380, Issue 9836, Pages 44-49 (July 2012)
Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial 
Sanne M Dorhout Mees, MD, Prof Ale Algra, MD, Prof W Peter Vandertop, MD, Fop van Kooten, MD, Hans AJM Kuijsten, MD, Jelis Boiten, MD, Prof Robert J van Oostenbrugge, MD, Rustam Al-Shahi Salman, PhD, Pablo M Lavados, MD, Prof Gabriel JE Rinkel, MD, Walter M van den Bergh, MD 
The Lancet 
Volume 380, Issue 9836, Pages (July 2012)
DOI: /S (12)
Copyright © 2012 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , 44-49DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

3. Figure 2
Distributions of mRS score in the magnesium and placebo groups
Data are number of patients with each mRS score. Tested with Mann-Whitney U test; p=0·95. mRS=modified Rankin Scale score.
The Lancet  , 44-49DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

4. Figure 3 Subgroup analyses for primary outcome
WFNS score was unknown for one patient. Treatment type was unknown for two patients. RR=risk ratio. WFNS=World Federation of Neurological Surgeons.12
The Lancet  , 44-49DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

5. Figure 4
Meta-analysis of effect of magnesium therapy after subarachnoid haemorrhage on poor outcome
The Lancet  , 44-49DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions